These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 29239680)

  • 1. The SPOTS System: An Ocular Scoring System Optimized for Use in Modern Preclinical Drug Development and Toxicology.
    Eaton JS; Miller PE; Bentley E; Thomasy SM; Murphy CJ
    J Ocul Pharmacol Ther; 2017 Dec; 33(10):718-734. PubMed ID: 29239680
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Slit Lamp-Based Ocular Scoring Systems in Toxicology and Drug Development: A Literature Survey.
    Eaton JS; Miller PE; Bentley E; Thomasy SM; Murphy CJ
    J Ocul Pharmacol Ther; 2017 Dec; 33(10):707-717. PubMed ID: 29111862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Species Differences in the Geometry of the Anterior Segment Differentially Affect Anterior Chamber Cell Scoring Systems in Laboratory Animals.
    Thomasy SM; Eaton JS; Timberlake MJ; Miller PE; Matsumoto S; Murphy CJ
    J Ocul Pharmacol Ther; 2016; 32(1):28-37. PubMed ID: 26539819
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of implantable intravitreal drug delivery technologies for the treatment of posterior segment eye diseases.
    Choonara YE; Pillay V; Danckwerts MP; Carmichael TR; du Toit LC
    J Pharm Sci; 2010 May; 99(5):2219-39. PubMed ID: 19894268
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Safety and Tolerability of Conjunctival Ring for Posterior Segment of the Eye.
    Kinoshita S; Ohguchi T; Noda K; Murata M; Yasueda SI; Obata H; Matsunaga T; Fukushima T; Kanda A; Ishida S
    Curr Eye Res; 2017 Aug; 42(8):1149-1154. PubMed ID: 28358216
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inflammation and immunogenicity limit the utility of the rabbit as a nonclinical species for ocular biologic therapeutics.
    de Zafra CLZ; Sasseville VG; Matsumoto S; Freichel C; Milton M; MacLachlan TK; Farman C; Raymond I; Gupta S; Newton R; Atzpodien EA; Thackaberry EA
    Regul Toxicol Pharmacol; 2017 Jun; 86():221-230. PubMed ID: 28322894
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exploratory drug safety: a discovery strategy to reduce attrition in development.
    Bass AS; Cartwright ME; Mahon C; Morrison R; Snyder R; McNamara P; Bradley P; Zhou YY; Hunter J
    J Pharmacol Toxicol Methods; 2009; 60(1):69-78. PubMed ID: 19422924
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rabbit intraocular reactivity to endotoxin measured by slit-lamp biomicroscopy and laser flare photometry.
    Nussenblatt RB; Calogero D; Buchen SY; Leder HA; Goodkin M; Eydelman MB
    Ophthalmology; 2012 Jul; 119(7):e19-23. PubMed ID: 22578448
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bioavailability and anticataract effects of a topical ocular drug delivery system containing disulfiram and hydroxypropyl-beta-cyclodextrin on selenite-treated rats.
    Wang S; Li D; Ito Y; Nabekura T; Wang S; Zhang J; Wu C
    Curr Eye Res; 2004 Jul; 29(1):51-8. PubMed ID: 15370367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances in ocular drug delivery: emphasis on the posterior segment.
    Kang-Mieler JJ; Osswald CR; Mieler WF
    Expert Opin Drug Deliv; 2014 Oct; 11(10):1647-60. PubMed ID: 24975820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. How Much Nonclinical Safety Data Are Required for a Clinical Study in Ophthalmology?
    Novack GD; Moyer ED
    J Ocul Pharmacol Ther; 2016; 32(1):5-10. PubMed ID: 26539734
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The PK-Eye: A Novel In Vitro Ocular Flow Model for Use in Preclinical Drug Development.
    Awwad S; Lockwood A; Brocchini S; Khaw PT
    J Pharm Sci; 2015 Oct; 104(10):3330-42. PubMed ID: 26108574
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The use of the African green monkey as a preclinical model for ocular pharmacokinetic studies.
    Glogowski S; Ward KW; Lawrence MS; Goody RJ; Proksch JW
    J Ocul Pharmacol Ther; 2012 Jun; 28(3):290-8. PubMed ID: 22235843
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Testing new drugs in the laboratory.
    Davey DG
    J R Coll Physicians Lond; 1977 Apr; 11(3):219-25. PubMed ID: 853461
    [No Abstract]   [Full Text] [Related]  

  • 15. Recent progress in ocular drug delivery for posterior segment disease: emphasis on transscleral iontophoresis.
    Myles ME; Neumann DM; Hill JM
    Adv Drug Deliv Rev; 2005 Dec; 57(14):2063-79. PubMed ID: 16310884
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Veterinary pharmacovigilance. Part 6. Predictability of adverse reactions in animals from laboratory toxicology studies.
    Woodward KN
    J Vet Pharmacol Ther; 2005 Apr; 28(2):213-31. PubMed ID: 15842309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanostructured lipid carriers as novel ophthalmic delivery system for mangiferin: improving in vivo ocular bioavailability.
    Liu R; Liu Z; Zhang C; Zhang B
    J Pharm Sci; 2012 Oct; 101(10):3833-44. PubMed ID: 22767401
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The principle of safety evaluation in medicinal drug - how can toxicology contribute to drug discovery and development as a multidisciplinary science?
    Horii I
    J Toxicol Sci; 2016; 41(Special):SP49-SP67. PubMed ID: 28250284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. General considerations in ocular toxicity risk assessment from the toxicologists' viewpoints.
    Onodera H; Sasaki S; Otake S; Tomohiro M; Shibuya K; Nomura M
    J Toxicol Sci; 2015 Jun; 40(3):295-307. PubMed ID: 25972191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rabbit ocular reactivity to bacterial endotoxin contained in aqueous solution and ophthalmic viscosurgical devices.
    Buchen SY; Calogero D; Hilmantel G; Eydelman MB
    Ophthalmology; 2012 Jul; 119(7):e4-e10. PubMed ID: 22578450
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.